Placeholder

Cancer: Harnessing the Power of the Immune System

$30.00

Copyright: This PDF purchase is for a Single user for review or filing purposes only. The PDF is watermarked. If you are interested in a PDF reprint to post on your website or distribute electronically, or hard-copy reprints, please contact Marah Walsh at mwalsh@pharmavoice.com.

Product Description

Cancer treatment is about to undergo a paradigm shift. Companies are making progress in using proteins, biomarkers, pathways, peptides, antigens, and other tools to trigger the body’s immune system to address cancer. This approach to immunotherapy incorporates an array of strategies based upon the concept of modulating the immune system to achieve a prophylactic and/or therapeutic goal.
Current cancer treatments typically destroy healthy cells along with the cancer cells they are meant to attack. Further, they do little to stop metastasis, the often-fatal spread of the disease to remote locations in the body. In contrast, companies now are developing approaches that trigger an immune response that can eliminate tumor tissue that has spread from the treatment site (metastatic tumors)…

Sidebar:
Selected Immunotherapies in Development

Experts on this Topic
Carl M. Cohen, Ph.D. Chief Operating Officer, Biovest International Inc., Worcester, Mass.; Biovest is developing individualized immunotherapies for life-threatening cancers of the blood system. For more information, visit biovest.com.
Craig Dees, Ph.D. CEO, Provectus Pharmaceuticals Inc., Knoxville, Tenn.; Provectus Pharmaceuticals specializes in developing oncology and dermatology therapies that are safer, more effective, less invasive, and more economical than conventional therapies. For more information, visit pvct.com.
Garnett Dezember. President, The Navicor Group, Westerville, Ohio; The Navicor Group, an inVentiv health company, is a full-service advertising agency that focuses exclusively on oncology and immunology. For more information, visit navicorgroup.com.
Christian Itin, Ph.D. CEO and President, Micromet Inc., Carlsbad, Calif.; Micromet is a biopharmaceutical company focusing on the development of novel, proprietary antibody-based products for cancer, inflammatory, and autoimmune diseases. For more information, visit micromet-inc.com.
Alan Melcher, M.D., Ph.D. Cancer Research, UK Senior Clinical Research Fellow and Senior Lecturer/Honorary Consultant in Clinical Oncology St. James’s University Hospital, Leeds, United Kingdom, and a Lead Investigator for Oncolytics Biotech Inc., Calgary, Canada; Oncolytics is a biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. For more information, visit oncolyticsbiotech.com.
Denis Miller, M.D. Senior Medical Director and Therapeutic Area Leader-Oncology/Hematology, Parexel International Corp., Waltham, Mass.; Parexel is a global bio/pharmaceutical services organization that provides a broad range of knowledge-based contract research, medical communications, and consulting services to the worldwide pharmaceutical, biotechnology, and medical-device industries. For more information, visit parexel.com.
Ide Mills. VP, Strategic Health Education, HealthEd, Clark, N.J.; HealthEd is a patient education agency. For more information, visit healthed.com.
Vafa Shahabi, Ph.D. Director of Research and Development, Advaxis Inc., North Brunswick, N.J.; Advaxis is a biotechnology company developing novel Listeria-based therapeutic cancer vaccines. For more information, visit advaxis.com.

FEEDBACK